Novo Nordisk Shares Tumble As Weight-Loss Drug Trial Data Disappoints

Print this page Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk, one of Europe’s largest companies, lost more than a quarter of its value on Friday after its latest obesity drug missed the drugmak ...Read more